داء الراصات الباردة: العلاج عندما لم يحقق ريتوكسيماب الاستقلالية عن نقل الدم

References

• Sutimlimab-jome is currently the only approved treatment of hemolysis for CAD.
• Therapies that target the classical complement pathway can be used to reduce transfusion requirements and improve anemia and fatigue.
• First complement inhibitor used for the treatment of severe CAD with primarily intravascular hemolysis.
• Results in increased mean hemoglobin levels within the first week.
• Repeat administration in patients with CAD inhibited hemolysis within 24 hours after administration, increased hemoglobin levels, and resulted in transfusion independence.
• Sutimlimab normalized mean bilirubin by week 1.